AI platform identifies anti-cancer uses in non-cancer generics

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/Tero Vesalainen)
(Image: Getty/Tero Vesalainen)

Related tags: Artificial intelligence, AI, Software, Generic drugs, Generics, Cancer

'Oncology Repurposing Engine' uses artificial intelligence to identify potential drug candidates among generics and off-patent drugs that may be repurposed as cancer therapies.

Eschborn, Germany-headquartered Innoplexus, an artificial intelligence (AI) software services company, announced a partnership with Cures Within Reach for Cancer, a nonprofit startup based in Boston, MA.

Per the partnership, Innoplexus will support the development of Oncology Repurposing Engine (ORE) a technology platform created by the nonprofit organisation to help identify new cancer treatments among existing non-cancer generic and off-patent drugs.

The ORE creates and then prioritizes the drug repurposing data that arise both from real-world evidence and scientific literature to create AI-powered decisions and reduce the time it takes to identify the potential anti-cancer effects of the drug products.

“The search engine will enable in hours, what would take years for human researchers to accomplish,”​ Innoplexus notes in the announcement.

According to the company, ‘hundreds’ of generic drugs approved by the US Food and Drug Administration (FDA) for non-cancer indications have shown ‘early signals’ of efficacy for treating cancer.

For some of these drugs, Innoplexus notes that only one definitive clinical trial is needed to determine whether it is effective for cancer, and therefore the time for the drug to reach the market as a cancer treatment is reduced.

Related topics: Bioavailability Challenge, Drug Delivery

Related news

Show more